[Federal Register Volume 64, Number 187 (Tuesday, September 28, 1999)]
[Notices]
[Page 52335]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-25201]



[[Page 52335]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel, Resynthesis of Therapeutic Agents 
for Treatment of Infectious Diseases.
    Date: October 8, 1999.
    Time: 8:30 a.m. to 4 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: Holiday Inn Bethesda, Connecticut Room, 8120 Wisconsin 
Avenue, Bethesda, MD 20892-7610.
    Contact Person: Nancy B. Saunders, PhD, Scientific Review 
Administrator, Scientific Review Program, Division of Extramural 
Activities, NIAID, NIH, Room 2217, 6700-B Rockledge Drive, MSC 7610, 
Bethesda, MD 20892-7610, 301-496-2550, [email protected].
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: September 21, 1999.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy, NIH.
[FR Doc. 99-25201 Filed 9-27-99; 8:45 am]
BILLING CODE 4140-01-M